Loading...

Transgene

DB:TGNA
Snowflake Description

High growth potential and slightly overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
TGNA
DB
€183M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Transgene SA, a biotechnology company, designs, develops, and produces therapeutic vaccines and oncolytic viruses for the treatment of cancer and infectious diseases. The last earnings update was 15 days ago. More info.


Add to Portfolio Compare Print
TGNA Share Price and Events
7 Day Returns
0.2%
DB:TGNA
0.4%
DE Biotechs
0.8%
DE Market
1 Year Returns
5.3%
DB:TGNA
-5.6%
DE Biotechs
-4.5%
DE Market
TGNA Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Transgene (TGNA) 0.2% 1% 1.6% 5.3% -1.7% -69.6%
DE Biotechs 0.4% 7.3% -6.5% -5.6% 51.9% 10.5%
DE Market 0.8% 6.9% 8.1% -4.5% 10.4% 13.9%
1 Year Return vs Industry and Market
  • TGNA outperformed the Biotechs industry which returned -5.6% over the past year.
  • TGNA outperformed the Market in Germany which returned -4.5% over the past year.
Price Volatility
TGNA
Industry
5yr Volatility vs Market

TGNA Value

 Is Transgene undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Transgene to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Transgene.

DB:TGNA Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 3 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 10.3%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:TGNA
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6.7%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.45
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.453 (1 + (1- 33%) (32.6%))
1.516
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.52
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.516 * 6.65%)
10.31%

Discounted Cash Flow Calculation for DB:TGNA using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Transgene is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:TGNA DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (EUR, Millions) Source Present Value
Discounted (@ 10.31%)
2019 -35.40 Analyst x2 -32.09
2020 15.35 Analyst x2 12.61
2021 20.84 Est @ 35.78% 15.53
2022 26.08 Est @ 25.12% 17.61
2023 30.68 Est @ 17.65% 18.78
2024 34.49 Est @ 12.42% 19.14
2025 37.52 Est @ 8.76% 18.88
2026 39.84 Est @ 6.2% 18.17
2027 41.60 Est @ 4.41% 17.20
2028 42.91 Est @ 3.16% 16.09
Present value of next 10 years cash flows €121.93
DB:TGNA DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= €42.91 × (1 + 0.23%) ÷ (10.31% – 0.23%)
€426.62
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= €426.62 ÷ (1 + 10.31%)10
€159.92
DB:TGNA Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= €121.93 + €159.92
€281.85
Equity Value per Share
(EUR)
= Total value / Shares Outstanding
= €281.85 / 62.37
€4.52
DB:TGNA Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:TGNA represents 0.98635x of ENXTPA:TNG
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.98635x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (EUR) x Listing Adjustment Factor
= € 4.52 x 0.98635
€4.46
Value per share (EUR) From above. €4.46
Current discount Discount to share price of €2.89
= -1 x (€2.89 - €4.46) / €4.46
35.2%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Transgene is available for.
Intrinsic value
35%
Share price is €2.89 vs Future cash flow value of €4.46
Current Discount Checks
For Transgene to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Transgene's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Transgene's share price is below the future cash flow value, but not at a substantial discount (< 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Transgene's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Transgene's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:TGNA PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in EUR €0.13
ENXTPA:TNG Share Price ** ENXTPA (2019-04-25) in EUR €2.93
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.58x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 20.1x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Transgene.

DB:TGNA PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ENXTPA:TNG Share Price ÷ EPS (both in EUR)

= 2.93 ÷ 0.13

22.73x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Transgene is overvalued based on earnings compared to the Europe Biotechs industry average.
  • Transgene is overvalued based on earnings compared to the Germany market.
Price based on expected Growth
Does Transgene's expected growth come at a high price?
Raw Data
DB:TGNA PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 22.73x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts
68.1%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.33x
Germany Market PEG Ratio Median Figure of 268 Publicly-Listed Companies 1.57x

*Line of best fit is calculated by linear regression .

DB:TGNA PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 22.73x ÷ 68.1%

0.33x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Transgene is good value based on expected growth next year.
Price based on value of assets
What value do investors place on Transgene's assets?
Raw Data
DB:TGNA PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in EUR €0.59
ENXTPA:TNG Share Price * ENXTPA (2019-04-25) in EUR €2.93
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.83x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.87x
DB:TGNA PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ENXTPA:TNG Share Price ÷ Book Value per Share (both in EUR)

= 2.93 ÷ 0.59

4.97x

* Primary Listing of Transgene.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Transgene is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Transgene's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Transgene has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

TGNA Future Performance

 How is Transgene expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
68.1%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Transgene expected to grow at an attractive rate?
  • Transgene's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Transgene's earnings growth is expected to exceed the Germany market average.
  • Transgene's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:TGNA Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:TGNA Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts 68.1%
DB:TGNA Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 3 Analysts 115%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.8%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:TGNA Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:TGNA Future Estimates Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2021-12-31
2020-12-31 101 20 49 3
2019-12-31 8 -28 -33 2
DB:TGNA Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2018-12-31 7 -28 8
2018-09-30 7 -29 -10
2018-06-30 7 -30 -29
2018-03-31 7 -33 -31
2017-12-31 7 -35 -32
2017-09-30 8 -36 -32
2017-06-30 9 -37 -31
2017-03-31 9 -35 -28
2016-12-31 10 -34 -24
2016-09-30 10 -37 -26
2016-06-30 9 -40 -28
2016-03-31 9 -43 -33

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Transgene's earnings are expected to grow significantly at over 20% yearly.
  • Transgene's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:TGNA Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below

All data from Transgene Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:TGNA Future Estimates Data
Date (Data in EUR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2021-12-31 -0.50 -0.50 -0.50 1.00
2020-12-31 0.24 0.30 0.18 2.00
2019-12-31 -0.53 -0.42 -0.61 3.00
DB:TGNA Past Financials Data
Date (Data in EUR Millions) EPS *
2018-12-31 0.13
2018-09-30 -0.16
2018-06-30 -0.44
2018-03-31 -0.48
2017-12-31 -0.52
2017-09-30 -0.50
2017-06-30 -0.47
2017-03-31 -0.45
2016-12-31 -0.43
2016-09-30 -0.55
2016-06-30 -0.72
2016-03-31 -0.85

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Transgene will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Transgene's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Transgene has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

TGNA Past Performance

  How has Transgene performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Transgene's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Transgene's year on year earnings growth rate has been positive over the past 5 years.
  • Transgene has become profitable in the last year making the earnings growth rate difficult to compare to the 5-year average.
  • Transgene has become profitable in the last year making it difficult to compare the Europe Biotechs industry average.
Earnings and Revenue History
Transgene's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Transgene Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:TGNA Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 7.08 8.03 6.99 17.95
2018-09-30 7.24 -10.39 6.28 18.11
2018-06-30 7.40 -28.80 5.57 18.27
2018-03-31 7.43 -30.54 5.62 20.07
2017-12-31 7.46 -32.27 5.67 21.86
2017-09-30 8.01 -31.58 5.79 21.81
2017-06-30 8.55 -30.89 5.90 21.77
2017-03-31 9.24 -27.54 6.07 19.69
2016-12-31 9.93 -24.18 6.24 17.62
2016-09-30 9.56 -26.04 6.22 18.58
2016-06-30 9.19 -27.89 6.21 19.54
2016-03-31 9.38 -32.90 6.01 21.54
2015-12-31 9.57 -37.91 5.80 23.54
2015-09-30 9.92 -39.78 6.26 24.67
2015-06-30 10.28 -41.64 6.72 25.80
2015-03-31 10.69 -41.38 7.15 26.17
2014-12-31 11.10 -41.12 7.58 26.53
2014-09-30 13.10 -40.97 7.47 28.24
2014-06-30 15.10 -40.83 7.35 29.94
2014-03-31 15.42 -41.84 7.06 31.80
2013-12-31 15.74 -42.86 6.77 33.66
2013-09-30 14.72 -43.73 6.67 33.94
2013-06-30 13.70 -44.60 6.56 34.23
2013-03-31 13.38 -43.90 6.59 34.00
2012-12-31 13.06 -43.19 6.61 33.78
2012-09-30 12.76 -45.45 6.58 45.57
2012-06-30 12.46 -47.71 6.56 57.36

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Whilst Transgene has efficiently used shareholders’ funds last year (Return on Equity greater than 20%), this is metric is skewed due to its high level of debt.
  • Transgene used its assets less efficiently than the Europe Biotechs industry average last year based on Return on Assets.
  • It is difficult to establish if Transgene improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Transgene's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Transgene has a total score of 1/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

TGNA Health

 How is Transgene's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Transgene's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Transgene is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Transgene's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of Transgene's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is not covered by short term assets, assets are 0.5x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Transgene Company Filings, last reported 3 months ago.

DB:TGNA Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 36.70 59.58 16.90
2018-09-30 36.70 59.58 16.90
2018-06-30 13.64 58.35 33.04
2018-03-31 13.64 58.35 33.04
2017-12-31 28.09 62.00 41.41
2017-09-30 28.09 62.00 41.41
2017-06-30 28.54 60.32 43.94
2017-03-31 28.54 60.32 43.94
2016-12-31 46.50 63.00 56.21
2016-09-30 46.50 63.00 56.21
2016-06-30 14.46 63.14 33.37
2016-03-31 14.46 63.14 33.37
2015-12-31 26.55 53.80 31.65
2015-09-30 26.55 53.80 31.65
2015-06-30 44.21 60.70 53.01
2015-03-31 44.21 60.70 53.01
2014-12-31 71.84 52.19 65.94
2014-09-30 71.84 52.19 65.94
2014-06-30 94.48 59.38 96.17
2014-03-31 94.48 59.38 96.17
2013-12-31 56.62 49.62 47.86
2013-09-30 56.62 49.62 47.86
2013-06-30 75.60 46.95 72.04
2013-03-31 75.60 46.95 72.04
2012-12-31 98.22 38.97 92.92
2012-09-30 98.22 38.97 92.92
2012-06-30 120.72 39.13 121.42
  • Transgene's level of debt (162.3%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (87.2% vs 162.3% today).
  • Operating cash flow is negative therefore debt is not well covered.
  • Unable to confirm if the interest payments on Transgene's debt are well covered by earnings due to lack of past financial data.
X
Financial health checks
We assess Transgene's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Transgene has a total score of 1/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

TGNA Dividends

 What is Transgene's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Transgene dividends. Estimated to be 0% next year.
If you bought €2,000 of Transgene shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Transgene's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Transgene's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:TGNA Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 326 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:TGNA Future Dividends Estimate Data
Date (Data in €) Dividend per Share (annual) Avg. No. Analysts
2021-12-31
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Transgene has not reported any payouts.
  • Unable to verify if Transgene's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Transgene's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Transgene has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Transgene's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Transgene's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Transgene afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Transgene has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

TGNA Management

 What is the CEO of Transgene's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Philippe Archinard
COMPENSATION €795,000
AGE 59
TENURE AS CEO 14.3 years
CEO Bio

Mr. Philippe Archinard, Ph.D., has been the Chairman of Transgene SA since June 17, 2010 and its Chief Executive Officer since December 6, 2004. Mr. Archinard serves as a Scientific Director of Mérieux Alliance Group. He began his served career with bioMerieux where he held various positions for 15 years in France and the United States, including Chief Executive Officer of the U.S. operations. He served as Director of the Immunotherapy Division - Institut Mérieux. He served as an Executive Director and Chief Executive Officer of Innogenetics N.V. from March 2000 to November 9, 2004 and also served its Managing Director. He has been a Director of Transgene SA since December 2004 and bioMérieux SA since June 10, 2010. He has been an Independent Director of ERYtech Pharma SA since May 6, 2013. He served as a Non-Executive Director of Innogenetics N.V., from November 9, 2004 to March 2005. Mr. Archinard holds a Degree in Chemical Engineering from the University of Montpellier (France) and received his PhD in Biochemistry from the University of Lyon (France) in 1985. In 1994, he completed the PMD program at the Harvard Business School (United States).

CEO Compensation
  • Philippe's compensation has been consistent with company performance over the past year.
  • Philippe's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Transgene management team in years:

5.3
Average Tenure
53
Average Age
  • The average tenure for the Transgene management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Philippe Archinard

TITLE
Chairman & CEO
COMPENSATION
€795K
AGE
59
TENURE
14.3 yrs

Christophe Ancel

TITLE
Deputy CEO & VP of Quality
COMPENSATION
€147K
AGE
53
TENURE
5.3 yrs

Jean-Philippe Del

TITLE
CFO & VP of Finance
AGE
37
TENURE
5.3 yrs

Elisabetta Castelli

TITLE
Director of Investor Relations
TENURE
11.3 yrs

John Felitti

TITLE
VP, General Counsel & Corporate Secretary
AGE
48
TENURE
3.1 yrs

Lucie Larguier

TITLE
Director of Corporate Communications & IR

Thibaut Fayet

TITLE
Vice President of Strategic Alliance
AGE
50

Philippe Slos

TITLE
Head of Preclinical Regulatory Laboratory
TENURE
14 yrs

Éric Quéméneur

TITLE
Deputy CEO and R&D Director
AGE
53
TENURE
4.6 yrs

Guy Crespy

TITLE
Executive Officer
AGE
71
Board of Directors Tenure

Average tenure and age of the Transgene board of directors in years:

18.3
Average Tenure
60
Average Age
  • The average tenure for the Transgene board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Board of Directors

Philippe Archinard

TITLE
Chairman & CEO
COMPENSATION
€795K
AGE
59
TENURE
8.8 yrs

Benoit Habert

TITLE
Independent Director
COMPENSATION
€30K
AGE
54
TENURE
19.3 yrs

Alain Merieux

TITLE
Non-Independent Director
AGE
80
TENURE
28.3 yrs

Dominique Takizawa

TITLE
Director
AGE
61
TENURE
17.3 yrs

Jean-Claude Weill

TITLE
Member of Scientific Advisory Board

Christopher Walker

TITLE
Member of Scientific Advisory Board

Rafick-Pierre Sékaly

TITLE
Member of Scientific Advisory Board

James Santo

TITLE
Member of Scientific Advisory Board

Pierre Coulie

TITLE
Member of Scientific Advisory Board

Pierre Chambon

TITLE
Member of Scientific Advisory Board
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Transgene's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Transgene has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

TGNA News

Simply Wall St News

TGNA Company Info

Description

Transgene SA, a biotechnology company, designs, develops, and produces therapeutic vaccines and oncolytic viruses for the treatment of cancer and infectious diseases. The company’s lead clinical-stage programs include TG4010, a therapeutic vaccine for the treatment of non-small cell lung cancer; Pexa-Vec, an oncolytic virus for the treatment of liver cancer; and TG4001, a therapeutic vaccine for cancers caused by the human papilloma virus. Its products in the clinical development stage also comprise TG1050, a therapeutic vaccine for the treatment of chronic hepatitis B; and TG6002, an oncolytic virus for the treatment of various solid tumors, such as glioblastoma, as well as for the cancers of the stomach, colon, pancreas, and bladder. Transgene SA has collaboration agreements with Bristol-Myers Squibb, Merck KGaA, Pfizer, and University of California Davis; licensing agreements with SillaJen, Inc. and Ascend BioPharmaceutical; agreements with, Sanofi, BioInvent, Randox, and Emergent BioSolutions Inc.; and collaboration and licensing agreement with Valneva; a strategic collaboration with NEC Corporation; and a collaboration with BioInvent International AB (publ) to co-develop multi-functional oncolytic viruses encoding for undisclosed antibodies sequences for treating a range of solid tumors. The company was founded in 1979 and is headquartered in Illkirch-Graffenstaden, France. Transgene SA is a subsidiary of TSGH SAS.

Details
Name: Transgene SA
TGNA
Exchange: DB
Founded: 1979
€182,755,102
62,373,755
Website: http://www.transgene.fr
Address: Transgene SA
400 Boulevard Gonthier d’Andernach,
Parc d’Innovation – CS80166,
Illkirch-Graffenstaden,
Alsace, 67405,
France
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ENXTPA TNG Ordinary Shares Euronext Paris FR EUR 30. Mar 1998
OTCPK TRGN.F Ordinary Shares Pink Sheets LLC US USD 30. Mar 1998
DB TGNA Ordinary Shares Deutsche Boerse AG DE EUR 30. Mar 1998
LSE 0OCQ Ordinary Shares London Stock Exchange GB EUR 30. Mar 1998
BATS-CHIXE TNGP Ordinary Shares BATS 'Chi-X Europe' GB EUR 30. Mar 1998
Number of employees
Current staff
Staff numbers
132
Transgene employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/25 20:35
End of day share price update: 2019/04/25 00:00
Last estimates confirmation: 2019/04/01
Last earnings filing: 2019/04/10
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.